Lea Eisenbach Professor Lea Eisenbach
The George F. Duckwitz Professor of Cancer Research
E-mail: lea.eisenbach@weizmann.ac.il
Phone: +972-8-934-4555
Fax: +972-8-947-4141
Location: Wolfson Bldg., Room 220


Publications (2002 - 2007)

  1. Barnea, E., Beer, I., Patoka, R., Ziv, T., Kessler, O., Tzehoval, E., Eisenbach, L., Zavazava, N., Admon, A. (2002). Analysis of endogenous peptides bound by soluble MHC class I molecules: A novel approach for identifying tumor specific antigens. Eur. J. Immunol. 32:213-222.

  2. Markel, G., Katz, G., Arnon, TI., Lotem, M., Bar-Haim, E., Blumberg, RS., Drize, O., Eisenbach, L., Mandelboim, O. (2002). Expression of CD66a (CEACAM1) on human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of human NK cell cytotoxicity. J. immunol. 168:2803-2810.

  3. Carmon, L., Bobilev-Priel, I., Brenner, B., Bobilev, D., Paz, A., Bar-Haim, E., Tirosh, B., Klein, T., Fridkin, M., Lemonnier, FA., Tzehoval, E., Eisenbach, L. (2002). Characterization of novel breast tumor-associated BA46-derived peptides in Db-/-xbeta2 microglobulin (beta2m)-/- null mice transgenic for chimeric HLA-A2.1/Db-beta2m single chain. J. Clin. Invest. 110:453-462.

  4. Cohen, CJ., Hoffman, N., Farago, M., Hoogenboom, HR., Eisenbach, L., Reiter, Y. (2002). Direct detection and quantitation of a distinct T cell epitope derived from tumor-specific epithelial cell-associated mucin (MUC1) using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 62: 5835�5844.

  5. Papo, N., Shahar, M., Eisenbach, L., Shai, Y. (2003). A novel lytic peptide composed of D, L amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. 278:21018-21023.

  6. Qimron, U., Madar, N., Bar-Haim, E., Eisenbach, L., Staats, HF., Porgador, A. (2002). Anti-cancer mucosal vaccines: therapeutic efficacy against cancers growing in mucosal organs. In: I.P. Witz (ed), "Proceedings of the 2nd international conference on tumor microenvironment." Monduzzi Editore, Bologna, Italy. pp. 197-206.

  7. Margalit, O., Eisenbach, L., Amariglio, N., Kaminski, N., Harmelin, A., Pfeffer, R., Shohat, M., G Rechavi, G., Berger, R. (2003). Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and F10.9 melanoma cell lines. British J. Cancer 89:314-319.

  8. Denkberg, G, Lev, A, Eisenbach, L, Benhar, I, Reiter, Y. (2003). Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 171:2197-2207.

  9. Lee, SH., Bar-Haim, E., Goldberger, O., Reich-Zeliger, S., Vadai, E., Tzehoval, E. Eisenbach, L. (2004). Expression of FasL by tumor cells does not abrogate anti-tumor CTL function. Immunol. Lett. 91:119-126.

  10. Markel G, Mussaffi H, Ling KL, Salio M, Gadola S, Steuer G, Blau H, Achdout H, de Miguel M, Gonen-Gross T, Hanna J, Arnon TI, Qimron U, Volovitz I, Eisenbach L, Blumberg RS, Porgador A, Cerundolo V, Mandelboim O. (2004). The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 103: 1770-8. Epud 2003 Nov 6.

  11. Lee, SH., Bar-Haim, E., Machlenkin, A., Goldberger, O., Volovitz, I., Vadai, E., Tzehoval, E., Eisenbach, L. (2004). In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Therapy 11:237-248.

  12. Qimron, U., Paul, L., Bar-Haim, E., Bloushtain, N., Eisenbach, L., Staats, HF., Porgador A. (2004). Non-replicating mucosal and systemic vaccines: Quantitative and qualitative differences in the Ag-specific CD8+ T cell population in different tissues. Vaccine 22:1390-1394.

  13. Bar-Haim, E., Paz, A., Machlenkin, A., Hazzan, D., Tirosh, B., Carmon, L., Brenner, B., Vadai, E., Mor, O., Stein, A., Lemonnier, FA., Fridkin, M., Cytron, S., Tzehoval, E., Eisenbach, L. (2004). MAGE-A8-overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. British J. Cancer 91:398-407.

  14. Berko, D., Carmi, Y., Cafri, G., Ben-Zaken, S., Sheikhet, H., Tzehoval, E., Eisenbach, L., Margalit, A., Gross, G. (2005). Membrane-anchored β2-microglobulin stabilizes a highly receptive state of MHC class I molecules. J. Immunol. 174:2116-2123.

  15. Machlenkin, A., Paz, A., Bar-Haim, E., Goldberger, O., Finkel, E., Tirosh, B., Volovitz, I., Vadai, E., Lemonnier, F., Tzehoval, E., Eisenbach, L. (2005). Human CTL Epitopes Prostatic Acid Phosphatase-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy. Cancer Res. 65: 6435-6442.

  16. Machlenkin, A., Goldberger, O., Tirosh, B., Paz, A., Volovitz, I., Bar-Haim, E., Lee, SH., Vadai, E., Tzehoval, E., Eisenbach, L. (2005). Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin. Cancer Res. 11:4955-4961.

  17. Stepensky, D., Tzehoval, E., Vadai, E., Eisenbach, L. (2006). O-glycosylated vs. non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clinical and Experimental Immunology143:139-149.

  18. Margalit, A., Sheikhet, HM., Carmi, Y., Berko, D., Tzehoval, E., Eisenbach, L., Gross, G. (2006) Induction of anti-tumor immunity by CTL epitopes genetically linked to membrane-anchored β2-microglobulin. J. Immunol. 176:217-224.

  19. Machlenkin, A., Azriel-Rosenfeld, R., Volovitz, I., Vadai, E., Lev,A., Paz, A., Goldberger, O., Reiter, Y., Tzehoval, E., Benhar, I., Eisenbach, L. (2007). Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol. Immunother. 56:217-26. Epub 2006 Jun 1.

  20. Issaeva, I., Zonis,Y., Rozovskaia,T., Orlovsky, K., Croce, CM., Nakamura, T., Mazo, A., Eisenbach, L., Canaani, E. (2007). Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol. Cell. Biol. 27, 1889�1903.

  21. Cohen, N., Stolarsky-Bennun, M., Amir-Kroll, H., Margalit, R., Nussbaum, G., Cohen-Sfady, M., Pevsner-Fischer, M., Fridkin, M., Bercovier, H., Eisenbach, L., Jung, S., Cohen, IR. (2007). Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages/dendritic cells: TLR-4 signaling induced by a conjugate vaccine or by LPS is required. (Submitted).

  22. Tirosh, B., Daniel Carmi, V., Carmon, L., Paz, A., Lugassy, G., Vadai, E., Machlenkin, A., Bar Haim, E., Do, MS., Ahn, IS., Fridkin, M., Tzehoval, E., Eisenbach, L. (2007). "1-8 interferon inducible gene family" - putative colon carcinoma associated antigens. (Submitted).

  23. Machlenkin, A., Uzana, R., Frankenburg, S., Eisenbach, L., Pitkovski, J., Gorodetsky, R., Peretz, T., Lotem, L. (2007). Membrane capture by tumor-reactive T cells: A novel concept in identification of functional cytotoxic T lymphocytes. (Submitted).

  24. Volovitz, I., Machlenkin, A., Tzehoval. E., Eisenbach, L. (2007). A prediction program for MHC class II binding peptides integrating mouse motifs determined experimentally. (Submitted).

  25. Volovitz, I., Marmor, Y., Machlenkin, A., Goldberger, O., Mor, F., Cohen, IR., Eisenbach, L. (2007). Utilizing split-immunity in the therapy of rat gliomas. (Submitted).

  26. Volovitz, I., Mor, F., Machlenkin, A., Goldberger, O., Marmor, Y., Cohen, IR., Eisenbach, L. (2007). Neonatal transplantation of T-cell immunity breaks tolerance to self antigens. (Submitted).

  27. Goldberger, O., Volovitz, I., Machlenkin, A., Vadai, E., Tzehoval, E., Eisenbach, L. (2007). Exuberated numbers of tumor-specific T cells result in tumor escape. (Submitted).

  28. Tavori, H., Tzehoval, E., Vadai, E., Goldberger, O., Kalchenko, V., Eisenbach, L. (2007). Cryoimmunotherapy: Antigen presentation by syngeneic versus semiallogeneic dendritic cells. (Submitted).

  29. Zhang, QJ., Li, XL., Huang, XC., Mathis, JM., Wang, D., Duan, WM., Shi, R., Eisenbach, L., Jefferies, WA. (2007). Expression of TAP and H-2Kb in tumor cells enhances killing activities of antigen-specific T cells. (Submitted).

  30. Bar-Haim, E., Machlenkin, A., Lee, SH., Volovitz, I., Goldberger, O., Tzehoval, E., Tirosh, B., Vadai, E., Porgador, A., Eisenbach, L. The Role of Direct and Indirect Antigen presentation for Immune Priming and Tumor Rejection (In preparation).

  31. Lee, SH., Goldberger, O., Vadai, E., Tzehoval, E., Eisenbach, L. Regression of IL-12 transfected tumor cells is dependent on γIFN but not on CTL or NK cells. (In preparation).

  32. Lee, SH., Vadai, E., Tzehoval, E., Eisenbach, L. Low tumorigenicity of IL-2 transduced Lewis lung carcinoma cells depends on NK cells that act through a perforin and γIFN independent mechanism (In preparation).